| __timestamp | Dynavax Technologies Corporation | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 20140000 |
| Thursday, January 1, 2015 | 22180000 | 37173000 |
| Friday, January 1, 2016 | 37257000 | 48616000 |
| Sunday, January 1, 2017 | 27367000 | 108488000 |
| Monday, January 1, 2018 | 64770000 | 244622000 |
| Tuesday, January 1, 2019 | 74986000 | 287000000 |
| Wednesday, January 1, 2020 | 79256000 | 354000000 |
| Friday, January 1, 2021 | 100156000 | 186000000 |
| Saturday, January 1, 2022 | 131408000 | 151000000 |
| Sunday, January 1, 2023 | 152946000 | 232600000 |
| Monday, January 1, 2024 | 267474000 |
Unleashing the power of data
In the competitive landscape of biotechnology, effective cost management is crucial. This analysis of SG&A (Selling, General, and Administrative) expenses from 2014 to 2023 for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation reveals intriguing trends. Ionis Pharmaceuticals, Inc. has consistently outpaced Dynavax Technologies Corporation in SG&A spending, peaking in 2020 with a 354% increase from 2014. Meanwhile, Dynavax's expenses surged by 760% over the same period, reflecting strategic investments in growth. Notably, 2023 saw Ionis reduce its SG&A expenses by 34% from its 2020 high, while Dynavax continued its upward trajectory, increasing by 15% from 2022. These trends highlight differing strategic priorities: Ionis appears to be optimizing costs, whereas Dynavax is expanding its operational footprint. Understanding these dynamics offers valuable insights into each company's strategic direction and market positioning.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and MorphoSys AG
Who Generates More Revenue? Ionis Pharmaceuticals, Inc. or Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Dynavax Technologies Corporation